Cambridge Healthtech Institute’s 8th Annual

Risk-Based Quality Management

Risk-Based Quality Management (RBQM) and Monitoring

14 - 15 October 2025 ALL TIMES CET (UTC +2h)

As risk-based quality management (RBQM) has evolved over the past decade, sponsors and regulators are embracing risk-based approaches to monitoring clinical studies. However, the pathway for implementation and operationalisation can vary depending on company size, maturity, and culture of innovation. Leveraging centralized monitoring, advanced data management strategies, and new technologies can help stay ahead of the curve when study conditions change quickly. However, challenges still arise, such as quality oversight of data, data validity, organizational change management, and regulatory developments. This conference will look at how risk-based approaches are executed by industry leaders and innovators, how these approaches are received by regulators, and what insights can be gleaned through case studies and lessons learned. The gathering will be part of the Summit for Clinical Trials Operations Executives (SCOPE) Europe, a two-day event made up of shared plenary keynotes from biopharma thought leaders, six conference tracks focused on specific issues and functions within the clin ops, innovation, and research enterprise, informal and interactive breakout discussion groups, and networking.

Monday, 13 October

13:00Registration Open

MONDAY AFTERNOON WORKSHOPS & USER GROUP (IN-PERSON ONLY)

13:45– 15:15 WORKSHOP 1: Nuts and Bolts of AI Implementation: What to Avoid and What to Emphasise (Sponsorship Opportunity Available)

INSTRUCTORS:
Jonathan Crowther, PhD, Head, Operational Design Center, Merck KGaA, Darmstadt, Germany
Prasanna Rao, Chief Products and Innovation Officer, Saama
This interactive workshop will provide a practical overview of key considerations for implementing AI in clinical operations and beyond. Topics will include ethical implications and regulatory updates such as the EU AI Act, a clear explanation of AI APIs and how they function, and best practices for effective prompt engineering. Attendees will gain valuable insights into common pitfalls to avoid and strategies to successfully integrate AI tools in a regulated environment.

15:00– 17:00 USER GROUP: Citeline Industry Roundtable (Invitation Only)

15:30– 17:00 WORKSHOP 2: Modernising Informed Consent: AI, Automation, and Ethics in Global Clinical Trials

INSTRUCTORS:

Pooja Bholanath Pagare, Manager, Clinical Development, ZS Associates

Kirstin Goldring, Senior Director/Head, HBS Compliance and Governance, AstraZeneca

Sofiane Nacia, Director, Senior Global Process Owner, Novartis

Hilde Vanaken, Head EFGCP eConsent Initiative, EFGCP – European Forum for Good Clinical Practice

Brenda Yanak, Former Vice President, Bristol Myers Squibb Co.; Founder, Clinical Transformation Partners LLC​

As clinical trials grow in complexity and scale, the role of informed consent becomes more critical—and more challenging—than ever. This interactive workshop explores the evolving landscape of consent in the digital age, from the automation of consent form development to navigating global ethics and privacy regulations. We'll examine the responsibilities embedded in consent language, new international policies designed to uphold participant rights, and the use of AI-powered tools to review, manage, and search consent documents for transparency and compliance. Designed for the broader clinical operations community, this session will be especially valuable for professionals focused on consent processes, patient recruitment, study start-up, site activation, decentralised trials, clinical technology, and clinical data. Attendees will leave with actionable insights into how technology can safeguard ethics while streamlining consent workflows across diverse trial environments.

17:15– 18:45 WORKSHOP 3: Tackling Kit Wastage for Greener Clinical Trials (Sponsorship Opportunity Available)

INSTRUCTORS:

Michael J. Cohen, MSc, MBA, SEP, Senior Director, Lead, Environmental Sustainability, Thermo Fisher Scientific
Thierry Escudier, Portfolio Lead, Pistoia Alliance
Celine Gervais, CEO, Quipment SAS 
Peter Morley, Clinical Sustainability Manager, Process Transformation & Digitalization, Novo Nordisk A/S
Diana Steinbuesch, Founding Member, Biospecimen Management Consortium (BMC); BioX Operations Portfolio Lead (Oncology), Roche

ESG (Environmental, Social, & Governance) Leaders in Pharma & Sustainable Trials Workshop at SCOPE. Join us for an insightful workshop on optimising clinical trial supply management. Discover strategies to minimise supply overage and kit wastage, while enhancing environmental sustainability. Learn from industry experts how to implement best practices that reduce waste, lower costs, and reduce greenhouse gas emissions in clinical trials. This workshop is essential for professionals committed to improving efficiency and sustainability in clinical research.​

Tuesday, 14 October

MORNING COFFEE AND CONFERENCE SESSIONS

06:45SCOPE Europe Fun Run

RUN COORDINATORS: 

Bridget Kotelly, Senior Conference Director, Cambridge Healthtech Institute
Eileen Murphy, Conference Producer, Production, Cambridge Healthtech Institute
Join SCOPE’s Coordinators on Tuesday morning for our Rise and Shine Fun Run! Don’t forget to pack your sneakers. All of us at Cambridge Healthtech Institute recognizse the importance of integrating well-being and fitness into our work travel routines. We're excited to offer our support to faculty, sponsors, and attendees in fostering a culture of wellness. This is an easygoing, informal running (or walking) event. No time chips, running bibs, or energy bars—just a laid-back opportunity for a small group to start the day on a positive note. You can sprint, run, jog, walk, jog-and-talk, or walk-and-talk—the goal is to get up and get moving! Meet us in the front lobby near the concierge at 6:45 am sharp! 

07:45Registration and Morning Coffee

08:50Organiser's Welcome Remarks

STUDY OVERSIGHT AND INSPECTION READINESS

08:55

Chairperson's Remarks

Keith Dorricott, Director, Dorricott Metrics & Process Improvement Ltd.

09:00

In Pursuit of Adoption: Risk-Based Quality Management and ICH E6 R3

Madeleine Whitehead, Process Excellence Leader, Product Development Quality Solutions, Roche Products Ltd.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use’s (ICH) renovation of Good Clinical Practice (GCP) represents a philosophical shift in the conduct of clinical research away from a one-size-fits-all approach to a more pro-active, risk-based approach. RBQM is the bedrock of drug development excellence: our goal is to enhance understanding and increase implementation of key topics detailed in ICH E6(R3). After soliciting direct feedback from our respective member companies, ACRO and TransCelerate have developed a set of tools to support the implementation of a strong foundation for quality in clinical development.

09:20

Risk Management and Centralised Monitoring Processes Applied and Demonstrated in Inspection Preparation

Miguel Valenzuela, Director, Clinical Risk & Analytics, Alnylam

Risk Management and Centralised Monitoring, having been established for some time, should be at the core of management and oversight processes on clinical trials. This presentation will share the sponsor experience of preparing for an inspection, and the inspectors’ expectations in contrast to the reality of RBQM in application.

09:35

Focusing on What Matters Most, Critical Thinking, and Collaboration: Implementing RBQM

Jess Gomes, RBQM Strategic Lead, Roche

In today's complex clinical trial ecosystem, focusing on what matters is paramount for study success and patient safety. Historically, the industry’s approach to quality and compliance has been retrospective with audits and inspections. Recent changes within the regulatory landscape demonstrate a paradigm shift towards a more prospective approach. Integral to this is functional stakeholder engagement and execution of critical thinking to facilitate inclusion of quality and focus on what matters most, from clinical trial design through all trial milestones. Dedication of resources on what impacts study data quality and reliability and patient safety equally aligns with principles of risk proportionality.

09:50 The Evolving Needs of RBQM, and How Technology is Having to Step Up to Meet the Challenge 

Duncan Hall, CEO & Founder, TRI

As RBQM adoption continues to accelerate under ICH E6(R3), so do the demands of sponsors and CROs. More and more so, RBQM is a driver for trial efficiency as well as quality, and as such is becoming more embedded into operational workflows. In this session Duncan will cover how the changing needs of RBQM are being met with RBQM technology, and what TRI are doing to ensure focus, confidence and efficiency in all RBQM led studies.

10:15 PANEL DISCUSSION:

Revealed: Emerging Best Practices in RBQM Oversight

PANEL MODERATOR:

Keith Dorricott, Director, Dorricott Metrics & Process Improvement Ltd.

Discussions at last year’s SCOPE Europe led to a group of experienced RBQM practitioners forming an expert working group to put together assets to help industry colleagues with RBQM challenges. The initial focus has been on oversight of RBQM – What is it? How is it best approached? How can you tell if RBQM is being implemented according to GCP? This panel will discuss the benefits of participating in expert work groups as well as provide insights into the rich discussions and outputs.

PANELISTS:

Johann Proeve, PhD, CSO, Cyn­tegrity

Linda White, Associate Director, Risk-Based Quality Management, Jazz Pharmaceuticals

Madeleine Whitehead, Process Excellence Leader, Product Development Quality Solutions, Roche Products Ltd.

10:40 AI-Augmented RBQM: Validated Algorithms Deliver Double-Digit Reductions in Risk-Review Cycle Times

Artem Andrianov, PhD, MBA, CEO & Founder, Cyntegrity

ICH E6(R3) raises expectations for data-driven Quality by Design. Cyntegrity’s GxP-validated AI mines completed trials and live eSource to auto-classify CTQs, suggest statistically robust KRI/QTL thresholds, and flag protocol deviations in near real time. Across recent multi-study deployments, the approach cut RBQM review cycles by a median 34%, freeing experts for root-cause prevention. The session details methods, guardrails, and lessons for scalable, inspection-ready RBQM.

10:53Grand Opening Coffee Break in the Exhibit Hall

The SCOPE Europe Exhibit Hall is the best place to fuel up with a mid-morning coffee while visiting with our many exhibitors. Learn about what’s new in the industry, connect with colleagues and partners, and make some new friends.

TUESDAY MORNING PLENARY SESSION: ACCELERATING THE FUTURE OF CLINICAL TRIALS: AI, EXECUTION, AND COLLABORATIVE DESIGN

11:49

Grab Your Seat: Plenary Keynote Seat Raffle & Prize Giveaway!* 

Micah Lieberman, Executive Director, SCOPE, Cambridge Healthtech Institute; Co-Founder, ClinEco

*Must be present to win!

11:50

Welcome to SCOPE Europe—Who Is Here and Why?

Micah Lieberman, Executive Director, SCOPE, Cambridge Healthtech Institute; Co-Founder, ClinEco

11:55Chairperson’s Remarks: Reimagining Clinical Research: Why Innovation, Speed, and Collaboration Must Converge Now

12:00 KEYNOTE PRESENTATION:

Transformative AI: Shaping the Future of Healthcare

James Weatherall, PhD, Vice President & Chief Data Scientist, BioPharmaceuticals R&D, AstraZeneca

Artificial intelligence is transforming medicines development, paving the way for enhanced patient outcomes and organisational success. By deriving actionable insights from complex datasets, we are accelerating the discovery of novel targets, elucidating intricate disease mechanisms, and improving how we approach clinical trials. The vast and exciting future applications of AI will deliver the next frontier in healthcare, urging us to reimagine innovation and advance science, with the goal of bringing new, better medicines to patients, faster.

12:25

Meet Your Neighbor: What Is YOUR Biggest Technological or Operational Challenge Right Now?

Micah Lieberman, Executive Director, SCOPE, Cambridge Healthtech Institute; Co-Founder, ClinEco

12:30 KEYNOTE CASE STUDY CO-PRESENTATION:

Learning from Lightspeed Execution of the OCEANIC STROKE Program

Alexander Krupp, PhD, Vice President, Executive Clinical Program Excellence Lead, Bayer AG

Georgios Tsivgoulis, MD, PhD, Professor of Neurology, National & Kapodistrian University Of Athens; President, Hellenic Neurological Society

More than 14 million patients experience a stroke every year. Preventing as many stroke events as possible will retain a high quality of life for patients, their caregivers, and society—and is therefore of high relevance. For Bayer’s OCEANIC program in stroke, we have established a product-centric operational model that has resulted in the competitor feedback: “You are killing us with excellence—how are you doing this?” In this keynote, we will explore how our industry can learn from high performance operating models to serve our patients faster, better, and at lower cost.

13:05 KEYNOTE PANEL DISCUSSION:

Closing the Gap between Protocol Development and Feasibility to Ensure Downstream Success with Sites and Patients

PANEL MODERATOR:

Ken Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

What are various companies doing to improve the gaps between protocol development, feasibility, and ops? Despite pharma companies' need to maintain their competitive edge, is there an opportunity for a collaborative industry feedback loop? Can this be collaborative/pre-competitive to improve efficiency and better serve sites and patients?

PANELISTS:

Bernhard Glombitza, Head, Clinical Operations EMEA and LATAM, Bayer

Christian Milliet, Head of Site & Healthcare Ambassadors, Clinical Development Operations, CSL Behring

Susana Ramos, PhD, Global Early Planning TA Lead, Clinical Sciences & Operations, Sanofi

Matthieu Ruffin, Head Study Leadership, SSO GCO Development, Novartis

13:35Join Your Peers for a Networking Luncheon in the Exhibit Hall

Take this opportunity to refresh and refuel with our Exhibit Hall lunch. Enjoy good food and even better conversation during our walk and talk luncheon.

TECHNOLOGIES DRIVING STUDY QUALITY

14:35

Chairperson's Remarks

Madeleine Whitehead, Process Excellence Leader, Product Development Quality Solutions, Roche Products Ltd.

14:40

Harnessing Data with the "DREaM" Browser for a True Data-Driven RBQM

Mateusz Kucyk, Director, RBQM, AstraZeneca

This talk will address the challenge of managing vast amounts of information about past and ongoing clinical trials scattered across multiple source systems and documents, which often remain underutilised. It will delve into the implementation of the Details, Risk, Errors, and Mitigations (DREaM) browser, showcasing an integrated process for extracting, collating, and analysing data to derive meaningful insights and support informed risk management and decision-making.

15:05 Predictive Analytics: Advancing Early Risk Detection in Clinical Trials

Laura Trotta, Vice President, Research Ops & Statistical Innovation, CluePoints SA

In this presentation, we explore the use of advanced analytics in clinical trials to enable an earlier detection of risks and enhance the predictive capacity of risk detection methods. By leveraging advanced models, we address the critical need for early risk detection and mitigation to ensure trial integrity and patient safety. This strategy entails employing methodologies capable of analysing temporal data and adapting dynamically to patient-specific characteristics throughout the study duration. Examples are presented for discussion.

15:30

Transforming Clinical Data Review with GenAI: From Manual Queries to Intelligent Workflows

Archana Nayak, PhD, Senior Data Scientist, Research and Development, Johnson & Johnson

Bhargava Reddy, PhD, Senior Director, Advanced Insights and Solutions, Janssen

At J&J, we are transforming clinical data review through AI-driven innovations that enhance automation, precision, and user experience. Our approach includes query optimization with BERT, smart autocomplete with RAG, duplicate detection, and natural language querying with FLAN-T5. These tools enable near real-time query optimization process, reducing delays and improving trial outcomes. This proactive, intelligent workflow bridges longstanding gaps, making data review more efficient and user-friendly, ultimately accelerating clinical decision-making and trial success.

15:55 360° Monitoring: A New Approach to Dynamic Clinical Oversight Using Centralized Insights

Olgica Klindworth, Vice President, Data Quality & Risk Management Solutions, Medidata a Dassault Systemes Co.

Lauren Price, Director Product Management CTMS, Product Mgmt CTMS, Medidata, Dassault Systemes

Manual data interrogation. Overlooked risks. Inefficient monitoring. It’s time to transform the outdated paradigm of clinical oversight with centralized, automated data insights that improve performance end-to-end, from guiding site selection decisions to fueling dynamic monitoring strategies. Anchored in a risk-based framework, this approach bridges protocol objectives with operational execution to maximize quality and efficiency. Join this session to learn how integrated solutions are redefining trial oversight and quality management for today’s complex clinical landscape.

16:20

From Trackers to Transformation: Scaling Oversight beyond Excel

Julia Movshovich, Associate Director, Global TA Lead for I&I and Rare Disease portfolio, Data Surveillance, R&D Clinical Development & Operations (CD&O), Clinical Data Sciences & Information Management, Pfizer

Manual trackers may get a trial off the ground, but they won’t scale a program. In this session, we’ll walk through a real-world use case of moving from spreadsheet chaos to a streamlined, tech-enabled oversight model. Learn how one team replaced disconnected trackers with integrated tools—reducing manual effort, boosting data quality, and unlocking capacity to do more with less. We’ll explore what changed (and what didn’t), lessons learned, and how to make smart, right-sized upgrades even without a giant tech budget.

16:57Reception in the Exhibit Hall with Beer, Wine, and Tapas

Wind down at the end of a busy session day with colleagues, beer, wine, and tapas. Have a drink with your favorite exhibitor and take a chance at winning a fabulous raffle prize (must be present to win)!

18:00Close of Day

Wednesday, 15 October

08:15Registration and Morning Coffee

LEVERAGING RISK-BASED APPROACHES TO STUDY PLANNING

08:45

Chairperson's Remarks

Łukasz Bojarski, Executive Director, Centralized Monitoring & Risk Based Quality Management, AstraZeneca

08:50

Optimising Early Development Trials—A Strategic Approach to Reduced Monitoring

Estelle de Bary, Global Study Manager, Sanofi

Anna Estrada Campmany, Early Development Project Leader, Oncology, Early Development Oncology, Sanofi

This presentation explores how reduced monitoring can enhance efficiency in early development clinical trials without compromising data integrity. By leveraging risk-based strategies and site partnerships, we can streamline oversight while maintaining regulatory compliance. Insights from feasibility planning and operational excellence will be shared, highlighting practical applications and future directions for optimising trial execution.

09:15

Transforming Clinical Quality: The Role of Analytics and Change Management

Agata Jarocka, Associate Director, Quality Investigations & Analytics, Process Quality and Transformation, AstraZeneca

In this presentation, we’ll explore how advanced analytics serve as a crucial driver of improvements in clinical quality and inspection readiness. By providing quality signals, identifying potential risks, and enhancing decision-making processes, analytics significantly boosts operational efficiency. We’ll delve into the critical interplay between analytics and change management strategies, discussing best practices for successful implementation of analytics within the organization. With real-world examples, attendees will discover how leveraging analytics can foster a culture of continuous improvement and substantially elevate organisational performance. The pivotal role of analytics in enabling clinical quality and effective change management will be a central discussion theme.

09:40

First Open Championships in Clinical-Study Risk Assessment 

Marcin Makowski, PhD, Head, Centralized Monitoring & Data Analytics, GlaxoSmithKline

During the session, the presenter will engage the audience in risk assessment of specific study designs. Participants will define critical-to-quality factors and key elements of their RBQM strategy. After that the real problems of the studies will be revealed. All cases will be based on real life stories.

10:17Coffee Break in the Exhibit Hall

More coffee, more exhibitors, more networking, and some delicious snacks. What’s not to love?

WEDNESDAY MORNING PLENARY SESSION: SCALING SMARTER TRIALS: NETWORKS, AI, AND THE NEW CLINICAL RESEARCH INFRASTRUCTURE

11:00

Networking Game, SCOPE Quiz & Prize Giveaway!

Micah Lieberman, Executive Director, SCOPE, Cambridge Healthtech Institute; Co-Founder, ClinEco

11:05Chairperson's Remarks

11:10 KEYNOTE PANEL DISCUSSION:

Embracing the Power of Networks to Expand Pharma's Research Footprint and Improve Recruitment

PANEL MODERATOR:

Terttu Haring, MD, Global Head, Engagement Strategy (Sites & Patients), Johnson & Johnson Innovative Medicine

In today’s complex clinical research landscape, strategic partnerships and connected networks are key to expanding reach and accelerating recruitment. This keynote panel brings together leaders from pharma, oncology, cardiology, and hospital networks across Europe to share how collaborative models are breaking down silos, improving patient access, and enabling faster, more inclusive trials. Panelists will discuss real-world examples of network-driven innovation and offer practical insights for scaling clinical research efficiently and equitably.

PANELISTS:

Javier Carmona, PhD, Head of Scientific Strategy & Translational Programs, Vall d’Hebron Institute of Oncology (VHIO); CSO, Cancer Core Europe

Astrid Schut, Managing Director, WCN (Werkgroep Cardiologische centra Nederland)

11:40 KEYNOTE PANEL DISCUSSION:

AI in Clinical Trials: Where Science Meets Systems—Bridging Operational Expertise with Technical Innovation

PANEL MODERATOR:

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News

Artificial intelligence is reshaping how clinical trials are designed, executed, and analysed—offering new efficiencies and deeper insights across the research continuum. This keynote panel will explore the intersection of scientific innovation and operational execution, highlighting how AI is being integrated into clinical development to enhance trial design, streamline data analysis, and support strategic decision-making. Expert panelists will discuss real-world applications, common implementation challenges, and the organizational shifts required to fully realise AI’s potential. Attendees will gain a clear view of how leading organisations are bridging the gap between advanced technologies and clinical operations to drive smarter, faster trials.

PANELISTS:

Jonathan Crowther, PhD, Head, Operational Design Center, Merck KGaA, Darmstadt, Germany

Janie Hansen, Business Systems Transformation, Global Development Information Management, Daiichi Sankyo, Inc.

Francis Kendall, Head of Statistical Programming, Digital and Data Sciences, Biogen

James Weatherall, PhD, Vice President & Chief Data Scientist, BioPharmaceuticals R&D, AstraZeneca

12:10Join your Peers for a Networking Luncheon in the Exhibit Hall

Join us again for lunch in the Exhibit Hall. Last chance to visit with exhibitors you missed and to enter our final raffle!

INTEGRATING RBQM ACROSS FUNCTIONAL AREAS

13:10

Chairperson's Remarks

Joanna Florek-Marwitz, Head, Risk Management & Centralized Monitoring, UCB Biosciences

13:15

Integration of RBQM and Quality throughout Organisational Functional Areas

Greg Cinciala, Senior Director, Clinical Quality Operations Lead, Clinical Trials, MSD

Helen Wong, Senior Director, RBQM Strategy and Implementation Lead, MSD

RBQM—Is this a shared responsibility among study management functional areas? Or is it a standalone concept? At MSD, we are currently undergoing a change in the approach of implementing RBQM principles, and we are restructuring the organisation and revising processes. With this presentation, we’d like to share our journey, lessons learned, and where we’re heading.

13:35

Strategic Shift—The RBQM Story at Novartis

Aurelie Dequelson, Head Risk Surveillance, Development, Novartis

Catalina Tirna, Head, Process and Risk Surveillance, Development, Novartis

At Novartis, implementing Risk-Based Quality Management (RBQM) has been more than a process, it’s been a strategic shift. By embedding our Process & Risk Surveillance (PRS) Team within the Business and building a strong partnership with Quality, we’ve enabled true cross-functional ownership of risk and integrated it directly into trial design and conduct, ensuring a strong feedback loop to global clinical trial processes. This session will share how we designed and operationalised our RBQM model, the key enablers for scaling it across the portfolio, and the lessons we've learned in making RBQM a core part of how we deliver clinical trials.

13:55 PANEL DISCUSSION:

How to Connect the Clinical Data Dots through the Risk-Based Quality Management Lens or What Is the Future of Risk-Proportionate Data Governance?

PANEL MODERATOR:

Joanna Florek-Marwitz, Head, Risk Management & Centralized Monitoring, UCB Biosciences

When the quality-by-design is clear from the very beginning to all stakeholders involved, when we apply the holistic view on the Critical to Quality (CtQ) factors to engage the multidisciplinary collaboration. and elevate risk communication, we are in a pole position to enable the adoption of risk proportionality in execution of clinical trials in general, and in clinical data management in particular. Instead of expecting perfect data, we need to “create a culture that values and rewards critical thinking and open dialogue about data quality and that goes beyond sole reliance on tools and checklists” (ICG-GCP E8R1 3.3.1),

PANELISTS:

Fabian Kuger, Senior Statistician, Centralized Monitoring Lead, Aesculap AG

Peter Stokman, Business Lead Reporting And reView ENvironment (RAVEN), Bayer AG

14:30Session Break

WEDNESDAY AFTERNOON PLENARY SESSION: THE FUTURE WE BUILD: RECOGNISING INNOVATION, RESTORING EUROPE’S ROLE, AND RECLAIMING THE PATIENT VOICE

14:35

Grab Your Seat: Plenary Keynote Seat Raffle & Prize Giveaway! (Sponsorship Opportunity Available)

Micah Lieberman, Executive Director, SCOPE, Cambridge Healthtech Institute; Co-Founder, ClinEco

14:40 CLINICAL RESEARCH NEWS' BEST-OF-SHOW AWARD:

Recognising Exceptional Innovation in Technologies Used by Clinical Research Professionals

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News

Sponsored by Clinical Research News & ClinEco
The 2025 Best-of-Show Awards offer exhibitors of the SCOPE Summit Europe an exclusive opportunity to distinguish and highlight their products, including innovative applications, technologies, tools, and solutions. The SCOPE community is invited to identify exceptional innovation in technologies used by life-science professionals, voting on the most impactful new products of the year. Submit your entry! https://www.scopesummiteurope.com/sponsor-exhibitor/best-of-show-awards

14:45 KEYNOTE FIRESIDE CHAT:

Trials Are Leaving Europe—Can We Bring Them Back?

Moe Alsumidaie, Chief Editor, Editorials, Clinical Trial Vanguard

Adama Ibrahim, Vice President, Digital Strategy & Change Management, Novo Nordisk

Tero Laulajainen, Vice President, Head of Global Clinical Operations, UCB

This keynote panel will address the decline in clinical trial activity across the European Union and what it will take to reverse the trend. Topics will include ethics review fragmentation, trial startup delays, cost pressures, site performance, and underrepresentation of EU citizens in global clinical trial data. The panel will explore how regulatory guidance, public-private collaboration, and ACT EU can collectively restore Europe's competitiveness in clinical development.

15:15 KEYNOTE FIRESIDE CHAT:

Patient Engagement to Shape Trial Design and Operations around Unmet Patients’ Needs

Alfonso Aguarón, Patient Advocate; Patient Engagement Director, Patvocates

Gonzalo Linares, Senior Director & Global Head, Patient Advocacy & External Engagement R&D, Johnson & Johnson AG

This dynamic session brings together the voices of industry and patients to explore how meaningful patient engagement can transform clinical trial design and execution. A pharma leader and a patient advocate will share real-world examples of collaboration that led to more inclusive protocols, improved recruitment, and enhanced trial experiences. Attendees will gain practical insights into embedding patient perspectives early and often to address unmet needs and drive better outcomes. Join us to learn how co-creating with patients is not just the right thing to do—it’s a strategic imperative.

15:40

Closing Remarks and Next Steps

Micah Lieberman, Executive Director, SCOPE, Cambridge Healthtech Institute; Co-Founder, ClinEco

15:45Close of Conference





No Agenda API URL configured.